Literature DB >> 16407878

Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis.

Julie M Blair1, Hong Zhou, Markus J Seibel, Colin R Dunstan.   

Abstract

The discovery of osteoprotegerin, receptor activator of nuclear factor kappa B (RANK) and RANK ligand as critical molecular determinants of osteoclastogenesis and regulators of bone resorption, has revolutionized our understanding of the processes of normal and pathological bone biology. Altering the relative biological availabilities of these molecules has direct consequences for the regulation of both bone resorption and bone remodeling. Importantly, recent research suggests a pivotal role for these molecules in mediating cancer-induced bone destruction. This review summarizes the current evidence of osteoprotegerin, RANK ligand and RANK involvement in the pathophysiology of skeletal metastasis, and of therapeutic targeting of this process.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16407878     DOI: 10.1038/ncponc0381

Source DB:  PubMed          Journal:  Nat Clin Pract Oncol        ISSN: 1743-4254


  40 in total

Review 1.  Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in diseases of the skeleton.

Authors:  Diptiman Chanda; Sanjay Kumar; Selvarangan Ponnazhagan
Journal:  J Cell Biochem       Date:  2010-10-01       Impact factor: 4.429

Review 2.  * Roughness and Hydrophilicity as Osteogenic Biomimetic Surface Properties.

Authors:  Barbara D Boyan; Ethan M Lotz; Zvi Schwartz
Journal:  Tissue Eng Part A       Date:  2017-11-04       Impact factor: 3.845

3.  Effects of the RANKL inhibitor, osteoprotegerin, on the pain and histopathology of bone cancer in rats.

Authors:  Martine P Roudier; Steven D Bain; William C Dougall
Journal:  Clin Exp Metastasis       Date:  2006-08-16       Impact factor: 5.150

Review 4.  Denosumab in breast cancer.

Authors:  Allan Lipton
Journal:  Curr Oncol Rep       Date:  2011-02       Impact factor: 5.075

Review 5.  From the ranks of mammary progesterone mediators, RANKL takes the spotlight.

Authors:  Rodrigo Fernandez-Valdivia; John P Lydon
Journal:  Mol Cell Endocrinol       Date:  2011-09-22       Impact factor: 4.102

6.  Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer.

Authors:  Windy Dean-Colomb; Kenneth R Hess; Elliana Young; Terrie G Gornet; Beverly C Handy; Stacy L Moulder; Nuhad Ibrahim; Lajos Pusztai; Daniel Booser; Vicente Valero; Gabriel N Hortobagyi; Francisco J Esteva
Journal:  Breast Cancer Res Treat       Date:  2012-12-15       Impact factor: 4.872

Review 7.  Animal models of cancer pain.

Authors:  Cholawat Pacharinsak; Alvin Beitz
Journal:  Comp Med       Date:  2008-06       Impact factor: 0.982

8.  Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in prostate cancer bone metastasis.

Authors:  Diptiman Chanda; Tatyana Isayeva; Sanjay Kumar; Jonathan A Hensel; Anandi Sawant; Girish Ramaswamy; Gene P Siegal; Matthew S Beatty; Selvarangan Ponnazhagan
Journal:  Clin Cancer Res       Date:  2009-11-17       Impact factor: 12.531

9.  Bone resorption increases tumour growth in a mouse model of osteosclerotic breast cancer metastasis.

Authors:  Yu Zheng; Hong Zhou; Colette Fong-Yee; James R K Modzelewski; Markus J Seibel; Colin R Dunstan
Journal:  Clin Exp Metastasis       Date:  2008-04-18       Impact factor: 5.150

10.  Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease.

Authors:  Y Y Yuan; P J Kostenuik; M S Ominsky; S Morony; S Adamu; D T Simionescu; D M Basalyga; F J Asuncion; T A Bateman
Journal:  Osteoporos Int       Date:  2007-11-24       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.